Log in | Register

Direct oral anticoagulants for venous thromboembolism prophylaxis in critically ill patients: where do we go from here?

Laurent Bertoletti| Martin Murgier| Henry T. Stelfox
Editorial
Volume 45, Issue 4 / April , 2019

Pages 549 - 551

No abstract available.

References

  1. Minet C, Potton L, Bonadona A et al (2015) Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care 19:287
    • View reference on publisher's website
  2. Alhazzani W, Lim W, Jaeschke RZ et al (2013) Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med 41:2088–2098
    • View reference on publisher's website
  3. Decousus H, Tapson VF, Bergmann J-F et al (2011) Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 139:69–79
    • View reference on publisher's website
  4. Ho KM, Chavan S, Pilcher D (2011) Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 140:1436–1446
    • View reference on publisher's website
  5. Duranteau J, Taccone FS, Verhamme P, Ageno W (2018) European guidelines on perioperative venous thromboembolism prophylaxis: intensive care. Eur J Anaesthesiol 35:142–146
  6. Schünemann HJ, Cushman M, Burnett AE et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2:3198–3225
    • View reference on publisher's website
  7. Bertoletti L, Ollier E, Duvillard C et al (2017) Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol Res 118:33–42
    • View reference on publisher's website
  8. Cohen AT, Spiro TE, Büller HR et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513–523
    • View reference on publisher's website
  9. Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167–2177
    • View reference on publisher's website
  10. Cohen AT, Harrington RA, Goldhaber SZ et al (2016) Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 375:534–544
    • View reference on publisher's website
  11. Chi G, Gibson C, Kalayci A et al (2019) Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. https://doi.org/10.1007/s00134-019-05565-6
  12. Niven DJ, McCormick TJ, Straus SE et al (2018) Reproducibility of clinical research in critical care: a scoping review. BMC Med 16:26
    • View reference on publisher's website
  13. Niven DJ, Rubenfeld GD, Kramer AA, Stelfox HT (2015) Effect of published scientific evidence on glycemic control in adult intensive care units. JAMA Intern Med 175:801–809
    • View reference on publisher's website
  14. Fowler RA, Mittmann N, Geerts WH et al (2014) Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. Trials 15:502
    • View reference on publisher's website
  15. Stelfox HT, Brundin-Mather R, Soo A et al (2019) A multicentre controlled pre-post trial of an implementation science intervention to improve venous thromboembolism prophylaxis in critically ill patients. Intensive Care Med 45:211–222

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement